Thomson Reuters Corp.: 1Q26 Legal Strength Highlights AI Adoption, But Competitive Overhang Persists

Core Conclusion

1Q26 Legal organic growth of 9% (11% ex-Fed cancellations) beat Morgan Stanley and consensus estimates by 100/70 bps, driven by accelerating GenAI product adoption—ACV from GenAI rose to 30% from 28% in 4Q25. EBITDA margin of 42.2% also exceeded forecasts. Despite the beat, the stock sold off after a large AI vendor announced new finance capabilities, confirming that AI disruption risk remains the primary valuation overhang. At ~14x NTM EV/EBITDA (3 standard deviations below the 5-year average), the market is pricing in material downside, but near-term catalysts are insufficient to resolve the debate.

Market Underappreciation of TRI's Data Moat

The market underestimates the structural durability of TRI's legal data advantage. Westlaw's 100+ years of editorially-enhanced US case law combined with Practical Law content creates a proprietary legal LLM (Thomson) that outperforms frontier models on specific tasks. This asset is not replicable by general AI tools. The current penetration trajectory—GenAI ACV share expanding 200-300 bps per quarter, CoCounsel monthly users quadrupled year-over-year, Westlaw Advantage users and searches up 7x in six months—suggests Legal growth can sustain near the high end of the 8-9% guidance range.

Evidence Chain

1. Legal organic growth 9% (ex-Fed 11%) outperformed MSe 8.0% and consensus 8.3%. Total company organic revenue growth of 8.0% exceeded MSe/consensus by 53/64 bps. (Exhibit 1)
2. GenAI product traction accelerating: ACV from GenAI reached 30% (28% in 4Q25, 15% five quarters ago). CoCounsel monthly active users quadrupled year-over-year; Tax, Audit & Accounting volume grew 5x since September 2025. Westlaw Advantage deep research users and searches up 7x in six months. (Report text)
3. EBITDA beat: Adjusted EBITDA $881M vs MSe $856M/consensus $860M; margin 42.2% ahead of MSe 41.8% and consensus 42.1%. (Exhibit 1)
4. Forward indicators positive: Next-generation CoCounsel to launch in 3Q26 with strong beta feedback. Management expects Legal revenue to land at the top of the 8-9% guided range. (Report text)

Key Risks

• Large AI vendors continue investing heavily in legal/finance tools; new finance module from a major AI vendor triggered the post-earnings selloff. If competitors develop sufficiently capable alternatives, TRI's data moat could be bypassed.
• Growth sustainability: Current elevated Legal growth partly reflects AI product pull-forward. If growth decelerates, the stock would face a disproportionate downside penalty—the market punishes deceleration more than it rewards acceleration.
• Macro headwinds: Government contract cancellations (impacting 200 bps of growth in 1Q26) and corporate budget tightening could persist.
• Reinvestment risk: AI product development and rollout may pressure margin expansion if cost outlays outpace revenue benefits.

Valuation & Trading Implications

Maintain Equal-weight rating and $116 price target (midpoint of DCF base case $161 and bear case $70), implying 16.6x 2026E EV/EBITDA. Current share price of $95.75 trades at ~14x NTM EBITDA, roughly 3 standard deviations below the 5-year historical average. This deep discount reflects the market's expectation of disruption, not a buying opportunity. The stock lacks a near-term catalyst to disprove bear arguments. Investors should wait for evidence of sustained Legal growth momentum or abating competitive headwinds—likely after the 3Q26 next-gen CoCounsel launch—before reassessing positions.